Welcome

In this Learning Zone:

• The global prevalence, burden and pathophysiology of UC
• Key unmet needs that impact UC management in practice
• Recommended treatment goals and management of UC, according to European and US guidelines
• Current and investigational treatments for UC, and how they relate to disease pathophysiology
• The importance of timely treatment decision-making, and stepping up treatment when required, considering recommendations for treatment sequencing and switching

Visit the expert opinion section and the roundtable discussion to hear insights on topics ranging from unmet needs and treatment goals to targeted small molecules and integrating the latest medications into clinical practice, with a focus on moderate-to-severe and refractory UC.

Meet the experts

The following experts provided insights into the management of UC throughout this Learning Zone.

Professor Stephen Hanauer

Stephen B Hanauer is a Professor of Medicine (Gastroenterology and Hepatology) and Medical Director of the Digestive Health Center at Northwestern University’s Feinberg School of Medicine in Illinois, USA. He is a board-certified internist and gastroenterologist, internationally recognised as an expert on the treatment of inflammatory bowel disease (IBD). Professor Hanauer has served as a member of the U.S. FDA Gastrointestinal Drugs Advisory Committee since 1987.

Disclosures: Professor Hanauer has been a consultant and involved in clinical research with AbbVie, Allergan, Amgen, Celgene, Genentech, GSK, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, and UCB Pharma. He has been involved in drug safety monitoring boards for Arena, Boehringer Ingelheim, Bristol Myers Squibb, Gossamer, Prometheus, and Protagonist. Professor Hanauer has also been a speaker for AbbVie, Janssen, Pfizer, and Takeda. He has also been a consultant for AstraZeneca, Cosmos, Catalys Pacific, Covance, Merck, Progenity, Salix, Samsung Bioepis, Seres Therapeutics, Sorriso, TLL Pharma, and VHsquared.

Dr Tim Raine

Dr Tim Raine leads the IBD clinical service and the IBD trials unit at Cambridge University Hospitals, UK. Dr Raine is the chair of the European Crohn’s and Colitis Organisation (ECCO) guidelines committee and is a lead author on several ECCO guidelines. His research focuses on the regulation of the gastrointestinal immune system, and is funded by the Wellcome Trust, CCFA, Crohn’s and Colitis UK, OpenTargets and the National Institute for Health Research.

Disclosures: Dr Raine has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, Janssen, LabGenius, Lilly, MSD, Mylan, Novartis, Pfizer, Roche, Sandoz, Takeda, UCB, and Xap Therapeutics.